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Abstract  1 
Background: Self-care advice and management of minor ailments have long been provided in 2 
community pharmacies across England. However, formal pharmacy minor ailment service provision 3 
is geographically variable and has yet to gain recognition and political support as a valued 4 
sustainable service for nationwide adoption and commissioning.  5 
Objective: To investigate the sustainability potential of pharmacy minor ailment services from the 6 
perspective of community pharmacy stakeholders within the North East of England.  7 
Methods: A mixed methods approach was adopted to survey and interview stakeholders from the 8 
North East of England who commission; provide; and/or represent groups influencing the design, 9 
delivery and investment in community pharmacy clinical and public health services. The 40-item 10 
Programme Sustainability Assessment Tool, a validated instrument to assess a public health 11 
programme’s capacity for sustainability across eight domains, was administered to fifty-three 12 
stakeholders, identified from a pharmacy minor ailments showcase event. The same stakeholders 13 
were invited for a semi-structured interview to explore issues further. Interviews were audio-14 
recorded, transcribed verbatim, and underwent framework analysis. 15 
Results: Forty-two (79.2% response rate) stakeholders representing commissioning, provider and 16 
influencing (e.g. Local Professional Network) organisations completed the assessment tool. 17 
Pharmacy minor ailment services were rated as unsustainable across the majority of the domains. 18 
Elements within the domain ‘Partnerships’ demonstrated potential for sustainability. Stakeholder 19 
interviews provided detailed explanation for the low scoring sustainability domains, highlighting the 20 
multifaceted challenges threatening these services. 21 
Conclusion: The Programme Sustainability Assessment Tool allowed stakeholders to evaluate the 22 
potential of pharmacy minor ailment services in England. Follow-up interviews highlighted that 23 
initial design and implementation of services was poorly conceived and lacked evidence, thereby 24 
impeding the services’ sustainability. There are many challenges facing a widespread provision of 25 
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pharmacy ailment services, but it is clear the profession needs to be clear on the service objectives 26 
to secure future interest and investment. 27 
 28 
Keywords: health service research; pharmacy practice; programme sustainability; minor ailments; 29 
self-care. 30 
 31 
Introduction 32 
A recent review of international pharmacy-based minor ailment services report that such services 33 
exist in Scotland, parts of Wales, parts of England and parts of Canada. They are also on the current 34 
political agenda in Australia, New Zealand and increasing parts of Canada. The review concludes that 35 
these services differ in their structural characteristics which need to be considered when assessing 36 
for success and sustainability.
1
 37 
The United Kingdom (UK) Nuffield report 1986 was one of the first documents that encouraged the 38 
diversification of the community pharmacists’ role away from routine prescription dispensing 39 
towards more public health roles such as providing self-care advice for minor ailments.
2
 To date, free 40 
pharmacy minor ailment services (PMAS) have been widely adopted by local authorities and 41 
commissioning groups be it in an uncoordinated and unstandardized manner.  42 
A review of PMAS in the UK carried out in 2011, found that more than half of the primary care 43 
organisations in England had reported commissioning and implementing one form of a PMAS.
2
 A 44 
subsequent systematic review included one randomised control trial amongst the large number of 45 
reviewed studies testing the effectiveness of minor ailments services. Clinical and humanistic 46 
outcomes were lacking and the focus was on symptom resolution, referral and reconsultation rates.
3
 47 
PMAS demonstrated similar performance in these measures to general practice (GP) and/or accident 48 
and emergency (A&E). However, due to the design of that research and lack of a non-randomised 49 
control, the findings are potentially less representative and widely applicable.
4 
 Further research has 50 
suggested that the mean costs, from the perspective of the UK National Health Service (NHS), were 51 
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significantly lower if patients were treated within the community pharmacy, but this is based on the 52 
assumption that the outcomes from medical practice and community pharmacy would be the same.
4
 53 
The lack of rigorous, outcomes-based research on PMAS, could be one factor that currently hinders 54 
national investment and equitable provision across the country. 55 
In 2016, an independent review of community pharmacy clinical services, commissioned by NHS 56 
England was carried out to help inform the future provision of clinical pharmacy services.
5
 This 57 
review suggests four thematic barriers to successful clinical service provision through community 58 
pharmacy. These included the recognised poor integration of community pharmacy within the wider 59 
NHS provision with the lack of digital interoperability as a key contributing factor. Prevailing 60 
behavioural (health-seeking behaviours) and cultural issues, pertaining to the perception of the roles 61 
and competencies of community pharmacists, within both the public population and healthcare 62 
professional communities, mean that community pharmacy often fails to be considered as a 63 
healthcare option. The overly complex and disjointed commissioning and regulatory systems were 64 
also reported to hinder the credibility of community pharmacy as an investable resource. Lastly, the 65 
varied funding routes, with the focus on a range of post-registration solutions to equip the 66 
workforce to be flexible to patient need, means the skill mix is diverse and utilisation of this 67 
workforce is ineffective.
5 
68 
These issues have not been specifically related to PMAS, and therefore their empirical applicability in 69 
explaining the lack of widespread adoption, and routinisation, of PMAS needs to be investigated. 70 
There is a developing interest to raise the awareness and appreciation of how implementation 71 
science will enhance understanding and inform the future advancement and spread of pharmacy 72 
practice innovation.
6
 Crespo-Gonzalez et al. promotes that, as services have been implemented and 73 
routinised into daily pharmacy healthcare provision, the next focus is to understand the 74 
sustainability of innovations to maintain and improve patient care over time.
7
 Sustainability has 75 
been described as the process of maintaining an innovation through continued innovation use 76 
integrated as routine practice; with ongoing capacity, a supportive environment and persistence of 77 
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benefits.
8
 A recent review of studies investigating public health interventions, with input from an 78 
expert panel, developed a conceptual framework for programme (intervention) sustainability in 79 
public health.
9
 The study defined an intervention’s capacity for sustainability as 80 
‘the existence of structures and processes that allow a programme to leverage resources to 81 
effectively implement and maintain evidence-based policies and activities’
9 
82 
Following the development of this conceptual framework, the Centre for Public Health Systems 83 
Science (CPHSS) at Washington University in St Louis developed the Sustainability Framework and 84 
the Programme Sustainability Assessment Tool (PSAT) to address the lack of reliable sustainability 85 
measurement tools. Based on consistency and reliability testing in a sample of 592 respondents 86 
representing 252 public health programmes, it was proposed that the PSAT has the capability to 87 
capture the distinct elements of programme sustainability.
10 
88 
This study aims to investigate the perceptions of commissioners, providers and representatives of 89 
groups who influence public health services, on the factors impacting the routinisation of PMAS and 90 
those contributing to the sustainability of PMAS. This will serve as a descriptive analysis to 91 
understand the barriers and facilitators to wide-spread adoption of PMAS and whether the process 92 
factors have limited the capacity to derive outcome-based evidence thus far. The cross-sectional 93 
perspective will also identify the crucial factors influencing the sustainability of PMAS going forward. 94 
 95 
Methods 96 
Design 97 
A sequential mixed methods approach was employed for this study to elicit the perspectives of 98 
stakeholders working in the commissioning, influencing and delivery of PMAS. The quantitative data 99 
was collected first and obtained by means of the self-completed PSAT questionnaire adapted for use 100 
within this study. Qualitative data collection was obtained following analysis of questionnaire data in 101 
the form of semi-structured interviews with participants. The aim was to investigate further the 102 
perceived: barriers and facilitators to coherent adoption and rountinsation of PMAS, and; issues 103 
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impacting the sustainability of PMAS quantitatively captured by the PSAT tool. Calhoun et al. 104 
commend the PSAT for its simplicity and accessibility to assess sustainability across a range of 105 
parameters. However, there is an acknowledgement that the tool is limited in providing a deep 106 
understanding of sustainability capacity. The authors recommend complementary discussions with 107 
stakeholders to explore nuances of setting and situation that the PSAT does not capture
11
, which 108 
provided the rationale for the sequential mixed methods approach. 109 
The study received ethical approval from the Research Ethics Committee of the Durham University 110 
School of Medicine, Pharmacy and Health (ESC2/2016/03). Participants were asked to provide 111 
written consent to participate in the semi-structured telephonic interviews. 112 
 113 
Setting 114 
The North East of England provides a region to investigate in detail the commissioning and delivery 115 
of PMAS. There are between 250-300 community pharmacies spread across this region, which 116 
includes some of the most deprived areas in England. This localised investigation aims to develop an 117 
in-depth understanding about the observed episodic and wavering support that has been afforded 118 
by PMAS across England as perceived by pharmacy stakeholders. 
 
119 
 120 
Participants 121 
Participants involved in the design, commissioning, operation and delivery of PMAS within the North 122 
East England were identified from a North East Minor Ailment Service Showcase event (March 2016) 123 
where these stakeholders were in attendance. Four areas within the North East presented their 124 
respective Minor Ailments service in terms of delivery and reflections on achievements at this event. 125 
The organisers of this event were able to provide an attendance list with job roles and contact 126 
details. Fifty-three attendees were identified from this attendance list and represented various 127 
organisations (commissioners, providers and influencers of services, e.g., representatives of the 128 
Local Pharmaceutical Committee (who have a role to influence the commissioning and provision of 129 
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public health services regionally), Clinical Commissioning Group (commissioner within a region), 130 
and/or community pharmacy healthcare team (service provider)) from within the commissioning 131 
landscape for public health services as illustrated in Figure 1. 132 
 133 
Figure 1. The commissioning landscape in the England (Adapted from Royal Society of Public 134 
Health).
12 
135 
(PSNC: Pharmaceutical Negotiating Services Committee: promotes and supports the interests of all NHS 136 
community pharmacies in England and is the body that represents NHS pharmacy contractors; LPC: Local 137 
Pharmaceutical Committee: represent all NHS pharmacy contractors in a defined locality. LPCs are recognised 138 
by local NHS Primary Care Organisations and are consulted on local matters affecting pharmacy contractors; 139 
Health and Wellbeing boards: forum where key leaders from the health and care system would work together 140 
to improve the health and wellbeing of their local population and reduce health inequalities; JSNA: Joint 141 
Strategic Needs Assessments: involves collecting and analysing data on the health state of a population and 142 
assessing the results to understand which aspects of health (and social care) need attention; JHWS: Joint 143 
Health and Wellbeing Strategies: these, with JSNAs, will form the basis of clinical commissioning groups, the 144 
NHS Commissioning Board and local authority commissioning plans, across all local health, social care, public 145 
health and children’s services; PNA: Pharmaceutical Needs Assessment: each health and wellbeing board must 146 
assess needs for pharmaceutical services in its area, and publish a statement of its first assessment and of any 147 
revised version; CCG: Clinical Commissioning Groups: consist of GP’s, other health professionals and lay 148 
members and are responsible for commissioning services for their local community  from any service provider 149 
which meets NHS standards and costs. They are expected to work with local organisations and partners to 150 
design services which meet the needs of the local population). 151 
 152 
These represented the population to administer the PSAT questionnaire and then sample for follow-153 
up interviews. The fifty-three identified stakeholders were contacted via email and provided with an 154 
electronic participant information sheet, the electronic PSAT and a consent form for the subsequent 155 
semi-structured interviews. 156 
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 157 
Data collection 158 
PSAT 159 
The 40-item PSAT questionnaire was electronically downloaded from the Centre for Public Health 160 
Systems Science website
13
 and assessed by the research team for face validity. Minor adaptations to 161 
the tool were required to tailor wording to the context and landscape of programme commissioning, 162 
and delivery within England. The face and content validity of the adapted tool was assessed by 163 
practicing pharmacists (n=10) at a regional professional meeting (May 2016). No further comments 164 
or suggestions were made to adapt the tool further. The tool contains recognises and defines eight 165 
domains of sustainability capacity as outlined in Table 1.  166 
Table 1. The eight domains of the PSAT to assess the sustainability of public health 167 
programmes/interventions.
9 
168 
Sustainability domains  
Funding sustainability Making long-term plans based on a stable funding environment.  
Political support Internal and external political environment which influences 
programme funding initiatives and acceptance. 
Partnerships  The connection between programme and community. 
Organisational capacity The resources need to effectively manage the programme and its 
activities. 
Programme adaptation The ability to adapt and improve in order to ensure effectiveness. 
Programme evaluation Monitoring and evaluation of process and outcome data associated 
with programme activities. 
Communications  The strategic dissemination of programme outcomes and activities 
with stakeholders, decision-makers, and the public. 
Strategic planning The process that defines programme direction, goals, and strategies. 
 169 
Each of the items spread across these domains assesses an element of sustainability. Respondents 170 
are required to rate the extent to which they perceive each element was present in the PMAS by 171 
using a Likert scale with anchors of 1 (“Little or no extent”) to 7 (“A very great extent”). The 172 
psychometric study of PSAT across its domains, items and with this scale has evidenced that this 173 
tool is reliable and ready to use for assessing capacity for sustainability.10
 
174 
The fifty-three stakeholders were emailed and invited to complete the PSAT (June 2016). An 175 
additional section was added to the questionnaire which asked for the respondents’ job role, 176 
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membership to any professional and/or pharmaceutical organisations and committees, and whether 177 
they were a qualified pharmacist. The questionnaires were sent out using the Bristol Online Survey 178 
(www.survey.bris.ac.uk), and were requested to be completed and emailed back within 14 days. 179 
Non-respondents were sent a reminder once this deadline had been reached and given a further 7 180 
days to submit their completed questionnaires. 181 
Semi-structured interviews 182 
An invite and consent form to participate in a telephonic interview was also sent out with the PSAT 183 
questionnaire to the fifty-three stakeholders. A semi-structured interview guide was used by the 184 
researcher to guide the conversation. The eight sustainability domains of the PSAT formed the main 185 
topics areas; the specific items of the tool were used to explore further the granularity of these 186 
factors. The four key barriers identified by the independent Clinical Services Review
5
 and the 187 
contributing issues (Appendix 1) were also included within the discussion to obtain rich and 188 
contextualised information about the stakeholders’ perspectives on the state of PMAS. Appendix 1 189 
shows how the four barriers map across to the sustainability domains and demonstrate relevance 190 
for discussion.  191 
These elements informed the interview guide to probe further the factors affecting routinisation and 192 
sustainability of PMAS. Interviews were conducted by phone by one researcher {HN} trained and 193 
skilled in qualitative research design. The interviewer, also a qualified pharmacist, ensured only the 194 
neutral cues and prompts that had been noted on the interview guide were used during the 195 
interview to limit the possibility of offering subjective opinion or critique. Interviews were audio-196 
recorded then transcribed verbatim.  197 
 198 
Data analysis 199 
The answers from the completed PSAT questionnaires were entered into Microsoft Excel.  200 
Respondents were classified as per their job role into ‘commissioner’, ‘representative of an 201 
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influencing group’ and/or ‘service provider’. Respondents also qualified as pharmacists were also 202 
identified. 203 
The mean of each of the PSAT 40 items were calculated from all respondents, as has been carried 204 
out in a study using the PSAT to evaluate the sustainability of a paediatric asthma care coordination 205 
programme.
14
 Overall domain scores were obtained by calculating the mean scores for each domain, 206 
and standard deviations were calculated to show variability across the items.  207 
The framework analysis approach as developed by Ritchie and Spence,
15
 was adopted for qualitative 208 
data analysis. The a priori themes were derived from the eight PSAT domains, with subthemes 209 
including the forty PSAT items and the issues identified in the clinical services review. To develop a 210 
coding scheme within this framework, transcripts from three randomly selected interviews were 211 
each independently coded by two evaluators to understand the data from different perspectives. 212 
Where difference was found, a third external party to the research team, was involved in discussions 213 
to adjudicate. Through constant comparison analysis of these initial transcripts,
16
 the a priori themes 214 
were adapted, and emerging themes were then added into the framework. The evaluators came to 215 
consensus on the final framework, which was the original framework plus an additional theme of 216 
‘strategies to overcome the barriers’. This version of the framework was tested by the two 217 
researchers, to analyse independently two more randomly selected interviews. On finding that no 218 
further themes were identified with this framework, the two researchers independently coded the 219 
remaining transcripts, comparing the generation of themes and development of the findings. 220 
 221 
In order to assure trustworthiness of this study as recommended by Lincoln and Guba:
17
 the 222 
methods and analyst triangulation enhances the credibility of the work; the ‘thick description,
17
 223 
yielded from the interviews about the context of PMAS design, delivery and commissioning within 224 
England will facilitate transferability of findings; the dependability of the study was augmented by 225 
the involvement of a third party, external to the research team not involved in research design or 226 
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collection, to provide an ‘external audit’
17
 to the research process and findings, and the combined 227 
effects of the triangulation and external audit enhances the confirmability of the study findings. 228 
 229 
Results 230 
Forty-two completed questionnaires were received from the stakeholders (79.2% response rate). All 231 
but one of the respondents (a service commissioner) were pharmacists, and most of the 232 
respondents (n=24, 57%) represented more than one job role as categorised from the self-reported 233 
professional/pharmaceutical memberships (service provider, commissioner, representative of an 234 
influencing group). 235 
The mean and standard deviations of the 40 PSAT items are shown in Figure 2. The respondents 236 
rated the majority of domains on the lower end of the Likert scale (<3) which indicates that PMAS 237 
currently exhibits ‘little or no extent’ to the listed elements recognised to support a sustainable 238 
programme. The ‘Partnership’ domain was rated slightly higher (4.1 ± 1.0), indicating there are some 239 
existing partnerships that improve the sustainability of PMAS (full data on mean scores and standard 240 
deviations per item are presented in Appendix 2). ‘Funding sustainability’ (1.7 ± 0.7) and ‘Strategic 241 
planning’ (1.7 ± 0.8) were particular domains that scored low across all respondents as 242 
demonstrated by a relatively narrow spread of scores. There was recognition that PMAS lacked 243 
stable and sustainable funding streams in an unsupportive economic climate, which contributed to 244 
the low score for ‘Funding sustainability’. The low score for ‘Strategic planning’ is attributed to low 245 
ratings on the items relating to perceived lack of sustainability and long-term financial plans, and 246 
that the programme goals and stakeholder roles and responsibilities are poorly understood. The two 247 
domains with the widest spread of scores across the component items were ‘Organisational 248 
capacity’ and ‘Programme adaptation’. Sub-group analysis was unable to demonstrate a significant 249 
difference in responses based on the reported role of the respondent. 250 
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 251 
Figure 2. The mean scores (± SD) for the domains of the PSAT awarded by the responding 252 
stakeholders (n=42). 253 
 254 
Twenty of the stakeholders provided consent for an interview. Most held more than one of the job 255 
roles, i.e. service provider, representative of an influencing group, commissioner. These twenty 256 
interviews were carried out between Sept-Nov 2016 and lasted on average 48 mins ± 12 mins. The 257 
qualitative data can be categorised by the eight domains of the PSAT. Interviewees provided in-258 
depth critique of the domains, and the issues impacting routinisation of PMAS and threats to its 259 
sustainability. A further theme emerged which focussed on key facilitators towards achieving 260 
improved sustainability capacity. These relate to underpinning concepts of successful 261 
implementation of an innovative service or programme. Fundamentally, the findings suggest that 262 
the current challenge to widespread adoption and future sustainability of PMAS can be ascribed to 263 
the perceived ill-informed and lack of evidence-base behind the initial service design and 264 
implementation. Each of the themes are described below. Verbatim quotes and codes to denote the 265 
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type of respondent (S: Service provider; I: representative of an influencing group; C: commissioner; 266 
P: Pharmacist) with specific PSAT items and their ratings have been provided in Appendix 3. 267 
Funding sustainability 268 
The majority of respondents emphasised the inadequate alignment and complexity of NHS funding. 269 
This is further confounded by the incentivisation towards driving quantity of prescription-related and 270 
clinical service activities not the quality of delivery and having little focus on patient outcomes.  271 
Some of the interviewees reflected that the current national structure, where community 272 
pharmacies provide NHS services under a Contractual Framework, combined with local clinical 273 
commissioning groups deciding additional service provision (namely ‘advanced and enhanced’),  274 
means that overall accountability and management of funding is complex.  275 
This has propagated the belief among the interviewees, that budgets to support the delivery of 276 
clinical services, such as PMAS, are held in siloes by professions. This has contributed to issues 277 
around poor integration of pharmacy in the wider NHS and lack of joined up healthcare provision. As 278 
such, interviewees related that funding and incentivisation at the local level is highly dependent on 279 
the specific drivers, skills and understanding of local commissioners and effectiveness of the 280 
relationship with local pharmacy influencers. There was also a view that pharmacy is not always 281 
represented at health policy and commissioning arenas and, in some cases where they are, the role 282 
of the community pharmacist may not be positively promoted. This may be due to professional 283 
isolation, where pharmacists working in commissioning or influencing organisations do not have 284 
clear understanding of pharmacy practice specifically within the area of community pharmacy, or 285 
due to poor relationships based on personal and/or professional perceptions.  286 
Environmental/Political support 287 
Competing payment structures between general practice and community pharmacy, exacerbated by 288 
the lack of awareness of the potential role of community pharmacy, was identified as a key barrier 289 
to the integration of community pharmacy in the wider NHS.  290 
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Further comments emphasised the lack of strong and visible pharmacy representation at local and 291 
national level to champion PMAS and gain support at the influencing and commissioning stages. 292 
Interviewees also acknowledged that there is currently a lack of coherency on what PMAS should be 293 
achieving, as there have been no clear performance indicators stipulated or description of what 294 
success looks like. This has resulted in a deficiency in evidence of effectiveness and outcomes, 295 
unable to support valid and credible business cases, and consequently achieving little or no buy-in 296 
from commissioners. 297 
Partnerships 298 
Respondents to the PSAT reported passionate commitment from within the pharmacy profession to 299 
the PMAS programme (mean rating 5.0 ± 0.7) and are engaged with the development of the 300 
programme (mean rating 4.3 ± 0.7). These high scores contributed to the overall high score for this 301 
domain. 302 
However, the semi-structured interviews revealed that this theme could provide an explanation for 303 
issues relating to the incongruity within pharmacy. The overwhelming feeling of the interviewees 304 
was that community pharmacy is often seen as professionally isolated, with very poor integration 305 
into local clinical teams but also within the various sectors of their own profession. Silo working was 306 
a predominant observation, where pharmacists working in different fields and/or roles (e.g. hospital 307 
vs. community, service provider vs. commissioner roles) lacked an understanding and appreciation 308 
of one another. This has been both a consequence of, and perpetuated by, the lack of strong 309 
relationships within the profession and with other healthcare professionals.   310 
As a consequence, awareness amongst other professionals of community pharmacy’s potential 311 
contribution is not harnessed towards better utilisation and integration in the wider NHS system. 312 
All interviewees referred to the poor understanding held by healthcare professionals of community 313 
pharmacy, related back to the silo working and detachedness from the NHS. Consequently, there is 314 
no coherent message externally projected by the NHS and healthcare providers within it, to promote 315 
the role of community pharmacy to the patients and public.  316 
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Organisational capacity 317 
There was a unanimous perception amongst the interviewees that community pharmacy was the 318 
best location for patients and public with minor ailments to access care, with easy accessibility to an 319 
appropriate level of knowledge, skills and expertise.  320 
However, despite the overall perceived support for PMAS delivery from community pharmacies, 321 
interviewees suggested that there was a lack of coherency amongst the pharmacy workforce: 322 
• Community pharmacists do not share information and learning of best practice with each 323 
other; 324 
• Community pharmacists do not have a consistent vision of their role in patient care and the 325 
wider NHS; 326 
• Community pharmacy lacks an effective scaffold to support and manage the establishment 327 
and maintenance of a collective vision of pharmaceutical care and strategy towards 328 
achieving it; 329 
• Community pharmacy lacks an effective communication strategy to ensure ‘on-the-ground’ 330 
service providers have an appreciation of the main objectives behind PMAS and how it aligns 331 
with the national political agenda around self-care. 332 
Some of the interviewees acknowledged that because of the lack of clear objectives around self-333 
care, support staff have been observed to divert patients and public away from self-care and provide 334 
treatments free under the PMAS.  This has had a detrimental impact on the perceptions of 335 
commissioners who observe this as an increased cost to be reimbursed by the NHS. This highlights 336 
the need for coherent collective awareness of the key purpose and political agenda of self-care 337 
underpinning PM S. 338 
Programme adaptation 339 
Interviewees recounted that episodic review of individual, local PMAS resulted in very little critical 340 
appraisal and only minor tinkering of superficial service details. There was an appreciation that 341 
PMAS needed a holistic critical overhaul to be fit for purpose. 342 
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Programme evaluation 343 
There is a lack of coherency of what PMAS should be achieving as there have been no clear 344 
performance indicators stipulated or description of what success looks like.  345 
A few interviewees did mention how digital integration through using PharmOutcomes, a web-based 346 
platform supporting clinical service delivery, has enabled better oversight of the service activity.  347 
However, the potential for sharing of information between healthcare professionals and within the 348 
profession was regarded as most appropriate to ensure joined up patient care. 349 
Communications 350 
Unsurprisingly the distorted vision and funding within the political and professional arenas is 351 
reflected in the reported variation of services and even the specifics of individual services that are 352 
provided from each pharmacy and each locality. As such the patients and public are confronted with 353 
a confusing picture of the role of community pharmacy as a profession and specific offerings within 354 
their geographical area.  355 
Some of the interviewees observed that there is very little engagement with the patients and public 356 
in the design of these services. Therefore, there is little understanding of patient behaviours and 357 
preferences, which would aid service design, implementation and delivery.  358 
Some interviewees channelled that the lack of buy-in and understanding amongst staff within 359 
community pharmacy of the NHS self-care agenda, could be the contributing factor to inappropriate 360 
marketing of PMAS and diversion of previously self-caring populations to the ever-growing burden of 361 
the NHS.  362 
Strategic planning 363 
Respondents observed that no one body, or collective, has claimed accountability and taken the so-364 
called ‘risk’ to: develop a PMAS; operationalise; govern; quality assure and evaluate towards 365 
optimising care, defining success, and providing evidence to improve future service design and 366 
commissioning. 367 
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There was reference to the Pharmaceutical Negotiating Services Committee, as an organisation that 368 
has been advocating for a national PMAS that was rejected just recently. There are also 369 
documentation and support provided online for contractors and pharmaceutical stakeholders 370 
towards developing business cases for PMAS.  371 
However, engagement with commissioning, influencing groups, providers and patient stakeholders 372 
was again recommended as key to service redesign at a national level. In this way, a shared vision 373 
aligned with the national healthcare agenda, and definition of ‘success’ could be established. 374 
The standardised PMAS should then be developed and a management and governance structure 375 
positioned to performance manage, quality assure and gather evidence of outcomes and impact. 376 
Until this is achieved, most respondents, despite being in favour of the further pursuance of PMAS 377 
for the patients and public, demonstrated low expectations of any significant developments in the 378 
near future for a more coherent system to support an effective PMAS. 379 
Strategies to improve sustainability capacity 380 
Many interviewees suggested that bringing together pharmacists and GPs at the service design and 381 
development stage would facilitate understanding and engagement towards delivering services that 382 
are focussed on the best patient care. Interviewees recommended that engagement with 383 
commissioning, influencing, providers and patient stakeholders is required in service redesign at a 384 
national level.  385 
Respondents proposed that there should be clear referral pathways to community pharmacy from 386 
GP practices, out of hour’s services and NHS 111 (the telemedical helpline) for appropriate patients 387 
to receive management for their complaints.  388 
One interviewee emphasised the importance for a service project manager that would monitor 389 
progress and outcomes and feed this back into service optimisation and delivery. Similar reflections 390 
were reported in other interviews; lack of accountability and responsibility of the management and 391 
performance monitoring of the service, and conversely how the survival of some of the individual 392 
services were due to the proactive initiatives of individuals to make it successful locally.  393 
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Every respondent highlighted the need to raise patient and public awareness of community 394 
pharmacy as an access point for healthcare advice and services. Suggestions were made for well-395 
planned campaigns and media coverage to divert patients away from the overburdened healthcare 396 
providers, e.g. A&E, GP surgeries.  397 
Positive press stories about community pharmacy were also recommended to offset the trend of 398 
only bad stories makes good news. However, there was no consensus amongst the interviewees on 399 
the who should do this and how to do it most appropriately to avoid misuse.  400 
Discussion  401 
This study offers an opportunity to reflect on the current delivery of a relatively long-running service 402 
and consider the potential contributing factors that have hindered wider adoption and threaten 403 
future prospects of the PMAS. It is also one of the first investigations that responds to a recent call 404 
to pharmacy practice research to focus on the sustainability stage of an intervention.
5
 The PSAT 405 
offers a useful assessment framework that maps across the characteristics for the sustainability 406 
phase as identified through a review of current literature undertaken by Crespo-Gonzalez et al.
7
 In 407 
this study, the tool was particularly pertinent as a guide for qualitative data collection, as it 408 
incorporated aspects that have been recently identified as barriers to the implementation and 409 
adoption of clinical services within community pharmacy.
5
 Therefore, streamlining the investigation 410 
of service routinisation and sustainability.  411 
The current success and survival of PMAS was attributed to the fact that there are diverse 412 
professional pharmacy organisations invested in the success of this service, e.g. LPC, Local 413 
Professional Networks; there is passion amongst the providers of this service (community pharmacy 414 
teams) and engagement  to develop the ultimate goals (high scoring items in the ‘Partnerships’ 415 
domain). PMAS was also scored relatively highly on the perception that there are adequate numbers 416 
and skilled staff to operate PMAS within community pharmacy (an individual items within the 417 
‘Organisational capacity’ domain). However, the general perspectives of the stakeholders involved in 418 
this study is that PMAS currently has low capacity for sustainability. Some of the key issues are 419 
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integral to the pharmacy profession, as there is a recognised lack of clarity on the purpose of PMAS 420 
as it relates to wider healthcare, and a need for a cohesive, credible representation in negotiating 421 
the role and potential contribution for community pharmacy. Externally there are also many issues 422 
pertaining to: the combination of centralised and devolved funding of community pharmacy 423 
services, which have been historically driving community pharmacy as a supply service; the deficient 424 
awareness of community pharmacy competency by other healthcare professionals and the public, 425 
meaning that community pharmacy is often not considered an integral part of the wider NHS. Lastly, 426 
operationally PMAS suffers from historical poor service design, development and implementation, 427 
and lacks the capability to evaluate and generate self-supporting evidence. 428 
This latter issue could be ameliorated by following the recommended steps of design, impact 429 
assessment and implementation phases of innovative service creation and delivery articulated in a 430 
recent review.
7
 Crespo-Gonzalez et al. describes that innovative services should be collaboratively 431 
designed and evidence informed. The service should be well defined in relation to the target 432 
population; context; objectives; methodology; outcomes and expected benefits. An impact 433 
assessment for key outcomes, patient and economic, via a pilot study would also test for feasibility, 434 
and a process evaluation would determine factors impacting service success.
7
 The design and 435 
implementation of PMAS has failed to follow this prescriptive series of activities, which has meant 436 
the implementation has been ill-informed, poorly-evidenced and lacking in empirical verification. 437 
Scheirer et al. suggest that investigation for sustainability be considered as an interlinked dynamic 438 
with adoption and implementation, rather than a stand-alone phase in the life-span of a service.
18
 439 
Consequently, it is the maturity of adoption and implementation that best determines the optimum 440 
time to assess for sustainability. From this study, it is clear that PMAS have yet to demonstrate 441 
sufficient adoption and implementation to appropriately determine sustainability.  442 
A recent comprehensive report by Watson et al. document a series of methodologies undertaken to 443 
determine the nature and extent of evidence to support PMAS. Authors also recognise incoherency 444 
amongst community pharmacy teams on the aim of the service. Clear and consistent 445 
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communications from the pharmacy profession are recommended to other healthcare professionals 446 
and the public on the potential of community pharmacy to provide care for minor ailments.
19
 A 447 
recent scoping review highlighted the importance of marketing activities to bridge the divide 448 
between community pharmacies and potential market, augmenting the success of a service.
20 
449 
The findings of this study suggest that the pharmacy organisation structural issues should be a 450 
priority towards progressing any investment in clinical service provision from community pharmacy. 451 
As such an established vision and voice will be achieved that will facilitate more coherent and 452 
transparent interprofessional relationships; provide a cohesive, holistic voice for the representation 453 
and negotiation of the pharmacy profession that policy-makers and commissioners will find hard to 454 
avoid. 455 
A key limitation to this study, aside from its derivation of findings from stakeholders based in one 456 
locality of England, is the absence of the patient perspective. It is crucial to consider service design 457 
and delivery in the context of patient acceptability and preferred health-seeking behaviour. There 458 
are studies that report that patients and the public have been satisfied with pharmacy minor ailment 459 
treatment
21,22
 and would be in favour for more pharmaceutical care of this nature in community 460 
pharmacy.
23
 Furthermore Hibbert et al. present an interesting perspective that the public are 461 
increasingly approaching self-care and minor ailment treatment from a consumerist perspective. 462 
Their study shows that the more prevalent ‘challenging consumers’ felt confident in their knowledge 463 
to self-treat their minor ailments and had a focus to buying a medicinal product. These tendencies 464 
were coupled with a reluctance to be questioned by a pharmacist and indifference towards 465 
pharmaceutical self-care advice.
24
 This dichotomous representation of the public presents its own 466 
challenges to the success of future PMAS, therefore signifying the importance of patient and public 467 
involvement in service redesign and delivery. 468 
 469 
Conclusions            470 
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Pharmacy Minor Ailment Services have been provided by community pharmacies across England for 471 
the past two decades. The service is unstandardised across the country and has failed to generate 472 
sufficient evidence to support a model of care delivery for national commissioning and adoption. 473 
Commissioners, community pharmacists and representatives of pharmaceutical organisations 474 
acknowledge that the challenges of implementation and future provision of the service are diverse 475 
and complex. Underlying and fundamental problems appear to be: the poorly executed design and 476 
implementation of PMAS at conception, and the lack of integrity of the pharmacy professional 477 
learning community. The former issue highlights the significance the service design and 478 
implementation process plays on service success, and assessment of sustainability is only of value 479 
once evidence-based implementation has led to routinized practice. The latter problem pertains to 480 
the organic nature of the profession, in which the negative effects have long since been recognised 481 
and reported on, however real progress has yet to be made in furthering efforts to create local and 482 
national learning communities within the profession. The Royal Pharmaceutical Society, the 483 
representative pharmaceutical professional body in the UK,  provide a platform both online and 484 
through local practice forums for networking opportunities which may in the future facilitate such 485 
professional learning communities to develop but evidence of this is yet to be reported.  486 
This study can be used to inform commissioners, service designers and providers on future service 487 
design, implementation and evaluation, by raising awareness of the supportive elements required to 488 
improve an intervention’s capacity for sustainability. 489 
 490 
 491 
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Appendix 1.The mapping of the thematic barriers to community pharmacy clinical services to the PAST eight domains of sustainability. 561 
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Barriers to 
community 
pharmacy 
providing clinical 
services  
Programme Sustainability Assessment Tool: Domains of Sustainability 
Funding 
sustainability 
Environmental/Political 
support 
Partnerships  Organisational  
capacity 
Programme 
adaptation 
Programme 
evaluation 
Communications  Strategic 
planning 
Integration 
- Part of the 
NHS Family 
- A member of 
the out-of-
hospital 
clinical team 
- Digital  
X X X X X  X X 
Behavioural 
- Public 
awareness and 
expectation 
- Pharmacy 
workforce 
- Perceptions of 
other health 
professionals 
 X X X X X X X 
System  
- Contractual 
issues 
- Contractor 
constraints 
- Commissioning 
constraints 
X X X X X X X X 
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 562 
Skill mix and 
workforce issues 
 X X X X X X X 
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Appendix 2. The mean scores from the respondents (n=42) for the 40-items spread across the eight 563 
sustainability domains . 564 
PSAT (8 domains and 40 items) 
 
Mean 
score 
(±SD) 
Environmental/Political Support 
1. Champions exist who strongly support the programme. 3.0 (0.8) 
2. The programme has strong champions with the ability to garner resources.  3.0 (0.7) 
3. The programme has leadership support from within the larger organisation. 3.0 (0.8) 
4. The programme has leadership support from outside of the organisation. 2.8 (0.6) 
5. The programme has strong public support. 3.0 (1.2) 
Funding Sustainability 
1. The programme exists in a supportive state economic climate. 2.1 (0.7) 
2. The programme implements policies to help ensure sustained funding. 1.7 (0.7) 
3. The programme is funded through a variety of sources. 1.6 (0.5) 
4. The programme has a combination of stable and flexible funding. 1.0 (0.0) 
5. The programme has sustained funding. 2.1 (0.9) 
Partnership 
1. Diverse community organisations are invested in the success of the programme.  3.8 (0.7) 
2. The programme communicates with community leaders. 3.4 (1.0) 
3. Community leaders are involved with the programme.  3.8 (0.8) 
4. Community members are passionately committed to the programme.  5.0 (0.7) 
5. The community is engaged in the development of programme goals.  4.3 (0.7) 
Organisational Capacity 
1. The programme is well integrated into the operations of the organisation. 2.9 (0.8) 
2. Organisational systems are in place to support the various programme needs. 2.0 (0.8) 
3. Leadership effectively articulates the vision of the programme to external partners. 2.3 (1.2) 
4. Leadership efficiently manages staff and other resources. 2.3 (0.7) 
5. The programme has adequate staff to complete the programme’s goals. 4.8 (0.8) 
Programme Evaluation 
1. The programme has the capacity for quality programme evaluation. 2.0 (0.7) 
2. The programme reports short term and intermediate outcomes. 1.6 (0.7) 
3. Evaluation results inform programme planning and implementation. 1.9 (1.1) 
4. Programme evaluation results are used to demonstrate successes to funders and 
other key stakeholders.  
2.3 (1.0) 
5. The programme provides strong evidence to the public that the programme works. 2.7 (1.2) 
Programme Adaptation 
1. The programme periodically reviews the evidence base. 2.0 (1.4) 
2. The programme adapts strategies as needed. 2.5 (1.0) 
3. The programme adapts to new science. 2.4 (1.0) 
4. The programme proactively adapts to changes in the environment. 2.5 (0.9) 
5. The programme makes decisions about which components are ineffective and 
should not continue.  
2.4 (0.9) 
Communications 
1. The programme has communication strategies to secure and maintain public 
support. 
1.8 (0.7) 
2. Programme staff communicate the need for the programme to the public. 1.5 (0.5) 
3. The programme is marketed in a way that generates interest. 1.5 (0.5) 
4. The programme increases community awareness of the issue. 2.2 (0.7) 
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5. The programme demonstrates its value to the public.  2.4 (0.5) 
 Strategic Planning 
1. The programme plans for future resource needs. 2.0 (1.0) 
2. The programme has a long-term financial plan. 1.8 (0.8) 
3. The programme has a sustainability plan. 1.2 (0.4) 
4. The programme’s goals are understood by all stakeholders. 1.5 (0.5) 
5. The programme clearly outlines roles and responsibilities for all stakeholders. 2.1 (0.7) 
 565 
 566 
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Appendix 3. The main themes generated from the qualitative analysis of interviews and illustrative verbatim quotes. (C: commissioner, S: service provider, 567 
P: pharmacist, I: representative of an influencer group; # denotes participant identifier code) 568 
 569 
Main themes and 
supporting PSAT item and 
rating 
Illustrative quotes 
Funding sustainability 
The programme exists in a 
supportive state climate, 
average rating 2.1 ± 0.7 
‘In the CCG, we don’t hold the core contract for community pharmacy, so people just kind of brush it off as actually this 
isn’t my job because we don’t hold the contract.’ (C, #4) 
 
‘I’m a pharmacist working in a CCG, and I’m not even going to claim to be an expert in commissioning and community 
pharmacy and service delivery, and I know quite a lot, because it’s an absolute minefield.’ (C, P, #2) 
The programme has 
sustained funding, average 
rating 2.1 ± 0.9 
‘The reality is, if budgets weren’t so siloed, it would make so much more sense to be pushing people through [PMAS], and 
keeping them out of A&E, walk-in centres, GP practices; it’s the most cost-effective means of treating a minor ailment, but 
we just can’t maximise its benefits because of budget lines.’ (I, S, P, #1) 
 
‘I don’t think they [commissioners] appreciate what community pharmacy could do, so I don’t think they have an 
understanding of the skill set that is already there and could be developed further. I think the financial constraints are 
what are overriding the CCGs , so it’s the bottom line that tends to put the block on everything, and sadly, I think some of 
our pharmacy colleagues, within medicines optimisation tend to be a block on community pharmacies being developed 
further.’ (I, S, P, #9) 
 
‘We’ve now got the on-the-ground GPs sitting on executives. Which means that if the GP has a poor relationship with 
community pharmacy, or has a perception that community pharmacy isn’t very good or very high quality or they have had 
a bad experience, those experiences are now escalated all the way through to those decision-making bodies.’ (I, S, P, #11) 
Environmental/Political support 
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Champions exist who 
strongly support the 
programme, average rating 
3.0 ± 0.8;  
The programme has strong 
champions with the ability 
to garner resources, average 
rating 3.0 ± 0.7 
‘I think conversations…have caused people to question the way they’ve been commissioned and it caused people to 
question their objectives with minor ailments and efficacy in terms of achieving those objectives.’ (C, P, #2) 
 
‘But how many patients are you redirecting [through PMAS}? How many GP appointments are you actually saving? When 
people go to pharmacy, are they getting the same standard of care? All these questions cannot be answered. So it’s very 
difficult to make a case.’ (C #4) 
 
 
Partnerships  
 ‘I am expecting them [CCG pharmacists], just because they have the word pharmacist and letters next to their name, 
they’ve got a degree in pharmacy, we expect them to be able to understand community pharmacy and how patients 
operate.’ (I, S, P, #7) 
 
‘I think that kind of baseline knowledge of experience of community pharmacy [speaking of pharmacists working within 
commissioning groups] does not give a good grounding for making decisions about community pharmacy, because you’ve 
never been a dispensary, they don’t know what the pressure is like in a community pharmacy. they don’t know what the 
skill mix is; they probably don’t even know how long a pharmacist trains for….When it comes to pharmacy, why would they 
need to know, because they’ve never had to know before, so why would they suddenly know now.’ (S, P, #20) 
 
‘I had a meeting with one [GP colleague] last night, and he was saying that we don’t know, we as in general practice, don’t 
know enough about community pharmacy, like their potential roles, and community pharmacy don’t know enough about 
general practice.’ (I, S, P, #19) 
Organisational capacity 
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The programme has 
adequate staff to complete 
the programme’s goals, 
average rating 4.8 ± 0.8 
‘it’s a no-brainer…business as usual..’ (I, S, P, #13) 
 
‘Accessibility and seven-day NHS and cost-effectiveness, no need for an appointment, all the barriers that are currently in 
place [referring to GPs]…are not there for community pharmacies to deliver that to the patient’ (S, P, #12) 
‘There isn’t even any peer reviews. So most often you’re a pharmacist on your own, so you will never be observed by 
another pharmacist to benchmark yourself….The infrastructure just isn’t in place to driver quality improvement.’ (I, S, P, 
#11) 
 
‘What we do lack is a coming together of pharmacists to chat stuff through’ (I, S, P, #5) 
‘I think there’s something about identity there, like what are all supposed to be achieving together…and it’s also about 
cultural change of the pharmacy staff.’ (I, P, #17) 
Organisational systems are 
in place to support the 
various programme needs, 
average rating 2.0 ± 0.8 
‘I think it’s about clinical leadership of the pharmacist at the pharmacy level. I don’t think we really equip community 
pharmacists in the best way that we could to fulfil roles of leading their staff, as seeing pharmacies as an NHS provider, 
who has obligations and something to offer the NHS.’ (I, P, #17) 
 
Leadership efficiently 
manages staff and other 
resources, average rating 
2.3 ± 0.7 
‘They are a diverse population [community pharmacy staff]. And trying to catch them all and trying to think about how to 
alter the way they kind of approach things like self-care and minor ailments will be challenging. I mean, education training 
is maybe the first step, but actually if we’re being realistic. That’s the tip of the iceberg.’ (I, S, C, P, #10) 
 
Programme adaptation 
The programme periodically 
reviews the evidence base, 
average rating 2.0 ± 1.4;  
The programme adapts to 
new science, average rating 
2.4 ± 1.0 
‘You have to go through a process with the commissioner; you have to do the engagement; you have to be looking at the 
evidence. You have to get buy in, in order to move anything forward. So you almost can’t tweak it at the edges, you kind of 
have to totally review and recommission or do nothing at all.’ (C, P, #2) 
‘But if you don’t engage your providers with service design to get the right design for your patients and your citizens and 
the providers, then actually your service is never going to work in the first place.’ (I, S, C, P, #10) 
 
Programme evaluation 
 ‘I think conversations…have caused people to question the way they’ve been commissioned and it caused people to 
question their objectives with minor ailments and efficacy in terms of achieving those objectives.’ (I, S, P, #19) 
‘We’ve moved it over to PharmOutcomes now…it certainly gives us more access to data. And then I guess more access to 
evidence of use of the service.’ (C #4) 
Communications 
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The programme has 
communication strategies to 
secure and maintain public 
support, average rating 1.8 ± 
0.7 
‘I’m pretty sure that XXXXX [locality] formulary is much more comprehensive than ours, the conditions that are on there, is 
bigger, and sort of longer than ours. So that suggests that they may be moving a little further ahead than we are.’ (S, P, 
#15) 
‘Now if the intention is to really push this service and take the pressure off the practices, we need to be seeing marketing 
and media on a regular basis. It doesn’t need to be constant in terms of media, but we need to see regular reminders to 
patients.’ (I, S, P, #11) 
 
‘It’s good news stories; it’s showing it’s working…that should hopefully be picked up nationally, and people will start to see 
a change.’ (I, S, P, #18) 
 
‘We were pushing for some sort of marketing and promotion of the scheme. The PCTs at the time weren’t at all keen on 
that, I guess on the basis that the more marketing you do, the more people will use it and the more pressure will be put on 
the budget. So it’s not something we’ve been able to promote consistently amongst community pharmacies. I mean, 
individual pharmacies will have their own bits and pieces …like stickers in windows, etc, but we probably won’t do that.’ (C, 
P, #2) 
Programme staff 
communicate the need for 
the programme to the 
public, average rating 1.5 ± 
0.5 
There’s been a lot…we talk to healthcare professionals who interact with us. They’ve said what they want, but we’re not 
necessarily very good at asking patients and the public what they want. And I think that probably is a big piece of work 
that really needs to be done before you do anything I think.’ (C, P, #2) 
 
‘Anecdotally there are reports that patients going to pharmacy, quite happy to buy it, and being directed then onto the 
scheme and then they’re querying ‘well, if we are moving into a self-care agenda nationally, how does it fit?’’ (C, P, #2) 
Strategic planning 
The programme has a 
sustainability plan, average 
rating 1.2 ± 0.4 
‘But the risk [to national rollout], the problem is no-one is brave enough to take that risk from a leadership perspective 
because they’re worried that if it’s not project managed appropriately then it could be a bottomless pit of money that 
could get out of hand.’ (I, S, P, #11) 
 
‘so there are ways of managing it and then you need someone to project manage a whole service, whether that’s done 
regionally or nationally, and the cost of having project managers compared to the cost if it all went pear-shaped is just a 
no-brainer.’ (I, S, C, P, #10) 
The programme ‘goals’ are 
understood by all 
stakeholders, average rating 
1.5 ± 0.5 
‘To move it forwards, it needs that clear mandate and it needs a clear one person to say have we got all the right 
stakeholders in the room, rather than one person trying to drive it off in different directions’ (I, S, P, #19) 
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Strategies to improve 
sustainability capacity 
‘We’ve got an enlightened CCG, obviously carefully informed by major pharmacy representatives locally. But they’re 
engaged and they understand and they went with a broad formulary [for the local MAS] which was excellent. Over in XXXX 
[locality], they have a very narrow formulary, which is informed by a very medicalised model of care. It’s very GP 
dominated in the CCG.’ (I, S, P, #16) 
 
‘I think the GPs, if their patients rocked up and wanted paracetamol or ibuprofen, they should not really give a prescription 
and give them a minor ailments leaflet. That might be a way of, sort of, training the patients not to go to their GP first, to 
go to the pharmacy.’ (S, P, #15) 
 
‘the reason a regional one is important because it will cover an NHS 111 catchment area and it will provide that 
standardised approach for patients to easily understand what they can get from community pharmacies and the 
healthcare practitioners so they can refer patients into it.’ (S, P, #20) 
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